Plasma PCSK9 Is a Late Biomarker of Severity in Patients With Severe Trauma Injury | Zendy

M. Le Bras | Zendy; Antoine Roquilly | Zendy; Valérie Deckert | Zendy; Cédric Langhi | Zendy; Fanny Feuillet | Zendy; Véronique Sébille | Zendy; Pierre-Joachim Mahé | Zendy; K. Bach | Zendy; Damien Masson | Zendy; Laurent Lagrost | Zendy; Philippe Costet | Zendy; Karim Asehnoune | Zendy; Bertrand Cariou | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Plasma PCSK9 Is a Late Biomarker of Severity in Patients With Severe Trauma Injury

Author(s) -

M. Le Bras,

Antoine Roquilly,

Valérie Deckert,

Cédric Langhi,

Fanny Feuillet,

Véronique Sébille,

Pierre-Joachim Mahé,

K. Bach,

Damien Masson,

Laurent Lagrost,

Philippe Costet,

Karim Asehnoune,

Bertrand Cariou

Publication year - 2013

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-4236

Subject(s) - pcsk9 , medicine , biomarker , endocrinology , cholesterol , lipoprotein , placebo , hydrocortisone , gastroenterology , ldl receptor , biology , pathology , biochemistry , alternative medicine

PCSK9 (proprotein convertase subtilisin kexin type 9) is a secreted protease that modulates cholesterol homeostasis by decreasing low-density lipoprotein receptor expression. Low levels of plasma lipoproteins are related to severity of illness and survival in patients of intensive care units (ICU).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research